Xencor (XNCR) Stock Analysis & Winston Score

Xencor is a biotechnology company that designs and engineers antibodies — proteins that can target and fight diseases like cancer and autoimmune conditions. Its main products are experimental drugs built using its proprietary XmAb technology platform, which modifies antibodies to make them work better or last longer in the body. The company sells licenses to its technology to larger pharmaceutical companies, including AstraZeneca, Novartis, and Alexion, while also developing its own pipeline of drugs. Xencor makes money two ways: collecting royalties and milestone payments when partners use its XmAb platform, and advancing its own drug candidates toward potential approval. It operates primarily in the United States and is a mid-sized biotech with a market cap around $1.5 billion. Its XmAb platform gives it a defensible intellectual property moat, but the company currently spends far more than it earns, and its financial future depends heavily on whether its internal drug pipeline produces successful clinical trial results.